Lunsekimig (SAR443765) is a bispecific antibody designed for asthma research, combining a nanobody against IL-13 with a VHH domain targeting TSLP. This investigational tool is utilized in preclinical in vitro and in vivo studies to explore mechanisms of dual cytokine inhibition in type 2 inflammatory pathways.